Orbitrap Fusion Lumos Tribrid Mass Spectrometer wins Scientists’ Choice Award for Best New Drug Discovery Product of 2015
This award recognizes the company with the highest reviews and ratings on SelectScience.
The global community of SelectScience readers and contributors has named the Thermo Scientific Orbitrap Fusion Lumos Tribrid Mass Spectrometer the Best New Drug Discovery Product of 2015. This award recognizes the company with the highest reviews and ratings on SelectScience, an online resource that fulfills the information needs of the global scientific community.
SelectScience announced the winner this week at an awards ceremony at the Annual Conference and Exhibition of the Society for Laboratory Automation and Screening (SLAS) in San Diego. Last year, the SelectScience community awarded the Thermo Scientific Vanquish High-Performance Liquid Chromatography system with Best New Separations Product and named Thermo Fisher Scientific as Company of the Year.
“This Scientists’ Choice Award celebrates the new technologies that made the biggest impact in drug discovery and development research in 2015,” said Arif Butt, CEO and founder of SelectScience. “The awards are unique in this industry as they empower scientists to nominate and vote for their favorite new product, enabling them to have their say in the manufacturers that have truly enabled their work. Congratulations to Thermo Fisher Scientific on this significant achievement.”
“We aim to deliver technology innovations that enable our customers to make impactful scientific discoveries,” said Dan Shine, senior vice president, analytical instruments at Thermo Fisher. “Ten years ago, we introduced the first Orbitrap-based mass spectrometer and this opened up new possibilities in life sciences research. Since then, we have continued to deliver new levels of performance for scientists conducting the most challenging work. We are proud that the scientific community recognizes the pioneering contributions of our newest addition, the Orbitrap Fusion Lumos MS.”
Scientists pushing the limits of quantitation and protein characterization require more expansive and in-depth analytical information. The Orbitrap Fusion Lumos Tribrid MS addresses this need for scientists conducting proteomics, biopharma and metabolomics research. The broad advances made in the new-generation Orbitrap Fusion Lumos MS instrument deliver increased sensitivity and an enhanced feature set, allowing scientists to perform more comprehensive sample analyses faster and with better accuracy than our mass spectrometers ever have before.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance